To date, these trials have proven their value, all things being equal, no reason for it not to the same for Phase 3.
Opthea won't know which patient got what dise or sham. However they do need to monitor in full the safety of the Phase 3 program, so they will be the very first to know of any adverse effects.
Ann: Opthea Appoints John Han, PharmD, as VP Medical Affairs, page-6
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
48.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $321.4M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10000 | 49.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 44.0¢ | 7766 | 1 |
View Market Depth
| Last trade - 19.00pm 10/06/2024 (20 minute delay) ? |
| OPT (ASX) Chart |
Day chart unavailable